Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - colistimethate sodium - powder for solution for injection/infusion - 2 million international units - polymyxins; colistin

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - colistimethate sodium - powder for solution for injection/infusion - 1 million international units - polymyxins; colistin

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levofloxacin hemihydrate - film coated tablet - 250 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levofloxacin hemihydrate - film coated tablet - 500 milligram

United States - English - NLM (National Library of Medicine)

chi research, inc. - achyrocline satureioides (unii: pga1az433z) (achyrocline satureioides - unii:pga1az433z), arctostaphylos uva-ursi leaf (unii: 3m5v3d1x36) (arctostaphylos uva-ursi leaf - unii:3m5v3d1x36), senna occidentalis (unii: n4u494dys5) (senna occidentalis - unii:n4u494dys5), mirabilis jalapa flowering top (unii: 623iwx4u2m) (mirabilis jalapa flowering top - unii:623iwx4u2m), petiveria alliacea whole (unii: 7ju9v35411) (petiveria alliacea whole - unii:7ju9v35411), physalis angulata (unii: w4tkw9d5gg) (physalis a - achyrocline satureioides 32 [hp_x] in 1 ml - for relief of symptoms of respiratory discomfort.  for relief of symptoms of respiratory discomfort.

United States - English - NLM (National Library of Medicine)

boiron - proteus inconstans (unii: utx536wn6n) (proteus inconstans - unii:utx536wn6n), proteus mirabilis (unii: c177vr41dv) (proteus mirabilis - unii:c177vr41dv), proteus morganii (unii: 56x6lid5zy) (proteus morganii - unii:56x6lid5zy), proteus rettgeri (unii: dk2qly70va) (proteus rettgeri - unii:dk2qly70va), proteus vulgaris (unii: 11t9hco30o) (proteus vulgaris - unii:11t9hco30o) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - potassium clavulanate, quantity: 7.4 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; hypromellose; aspartame; succinic acid; xanthan gum; colloidal anhydrous silica; flavour - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin should not require the addition of another antibiotic due to the amoxicillin content of augmentin.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 500 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 250 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate, quantity: 575 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: sodium starch glycollate; purified talc; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic) h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic) p. mirabilis; s. faecalis; e. coli (see microbiology). gonorrhoea n. gonorrhoea (non-penicillinase producing). prophylaxis of endocarditis amoxycillin may be used for the prophylaxis of bacterial en